Cambridge, UK, 12 January 2004 - CeNeS Pharmaceuticals plc (LSE: CEN)
("CeNeS" or "the Company"), is pleased to announce the appointment of
Piper Jaffray Ltd. as its nominated adviser and joint financial
adviser, and Nomura International plc as its sole broker and joint
financial adviser, with immediate effect.


For more information please contact:

CeNeS Pharmaceuticals plc
Neil Clark
Tel: +44 (0)1223 266466

Piper Jaffray Ltd.
David Wilson
Tel: 44 (0)20 7743 8700

Nomura International plc
David Rasouly
Tel: 44 (0) 20  7521 2000

Capital MS&L
Mary Clark
Tel: +44 (0)20 7878 3245

This news release contains forward-looking statements that reflect
the Company's current expectation regarding future events.
Forward-looking statements involve risks and uncertainties. Actual
events could differ materially from those projected herein and depend
on a number of factors including the success of the Company's
research strategy, the applicability of the discoveries made therein,
the successful and timely completion of clinical studies and the
uncertainties related to the regulatory process.

Notes to Editors:

CeNeS is a biopharmaceutical company specialising in the discovery,
development and commercialisation of drugs for the treatment of pain
and disorders of the central nervous system. The company is based in
Cambridge, England. For further information visit www.cenes.co.uk



- ---END OF MESSAGE---
Copyright � Hugin ASA 2004. All rights reserved.